Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Catalyst Pharmaceutical Partners Inc


Tuesday, 12 Nov 2013 07:15pm EST 

Glancy Binkow & Goldberg LLP announced that a class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of a class (the Class) comprising all purchasers of the securities of Catalyst Pharmaceutical Partners Inc between October 31, 2012 and October 18, 2013, inclusive (the Class Period). The Complaint alleges that the defendants failed to disclose that one of Catalyst`s competitors - a private pharmaceutical company - has been manufacturing a drug biologically equivalent to Firdapse, and providing it to patients with LEMS, free of charge, through a compassionate use program. On October 18, 2013, an article published by The Street stated that Catalyst`s Firdapse was the same drug that its competitor has been manufacturing and providing in the U.S. for at least two decades. 

Company Quote

2.06
0.03 +1.48%
17 Apr 2014